Is standby therapy for Covid-19 a practical option for travellers?

Chen, Lin H; Connor, Bradley A

Chen, Lin H; Connor, Bradley A.

Chen LH; Department of Medicine, Mount Auburn Hospital, Cambridge, Massachusetts, and Harvard Medical School, Boston, Massachusetts.
Connor BA; Department of Medicine, Weill Cornell Medical College and the New York Center for Travel and Tropical Medicine, New York, New York.

J Travel Med ; 2022 Sep 24.

Article in English | MEDLINE | ID: covidwho-2077807

ABSTRACT

ABSTRACT

International travel has resumed while the risk of SARS-CoV-2 persists, leading to consideration of medications that can treat or prevent Covid-19 when travellers become ill abroad. Nirmatrelvir-ritonavir, molnupiravir, and tixagevimab-cilgavimab are available under Emergency Use Authorization or conditional approval. We discuss the potential application of these medications to protect travellers.

Keywords

antiviral; authorization; immunocompromised; molnupiravir; monoclonal; nirmatrelvir-ritonavir; tixagevimab-cilgavimab

Fulltext

XML

PubMed Links

Search on Google

Full text: Available Collection: International databases Database: MEDLINE Type of study: Prognostic study Language: English Journal subject: Communicable Diseases / Public Health Year: 2022 Document Type: Article

Similar

MEDLINE

LILACS

LIS

Fulltext

XML

PubMed Links

Search on Google